Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.24.

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Pulse Biosciences (NASDAQ:PLSE) has seen its share price rise 165% over the last year ...

Pulse Biosciences: Bioscience That Doesn't Get Our Pulse Racing Jan. 22, 2020 8:00 AM ET Pulse Biosciences, Inc. (PLSE) Stock APYX , CUTRQ , SOLY , PLSE 12 Comments Marvl Research ...

Pulse Biosciences Price Performance Shares of NASDAQ:PLSE opened at $16.09 on Monday. The firm has a 50 day moving average of $18.78 and a 200 day moving average of $18.15.

Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced a ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ETCompany Participants. Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO ...

Pulse Biosciences, Inc., a novel bioelectric medicine company progressing Nano-Pulse Stimulation TM technology, announced today that on December 31, 2020, it delivered a notice of redemption to ...

Operator: Greetings, and welcome to the Pulse Biosciences First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.